Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Literature DB >> 12183266

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Sofia Perea¹, Gloria Gonzalez, Annette W Fothergill, William R Kirkpatrick, Michael G Rinaldi, Thomas F Patterson.

Abstract

The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of <1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 12183266 PMCID： PMC127429 DOI： 10.1128/AAC.46.9.3039-3041.2002

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.

Authors: N S Ryder; I Leitner
Journal: Med Mycol Date: 2001-02 Impact factor: 4.076

2. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors: A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

3. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors: Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

4. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors: G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191

5. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors: K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191

6. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors: M Weig; F M Müller
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

7. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors: A Espinel-Ingroff
Journal: J Clin Microbiol Date: 1998-01 Impact factor: 5.948

8. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors: T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal: Medicine (Baltimore) Date: 2000-07 Impact factor: 1.889

9. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors: S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

Review 10. Current and emerging azole antifungal agents.

Authors: D J Sheehan; C A Hitchcock; C M Sibley
Journal: Clin Microbiol Rev Date: 1999-01 Impact factor: 26.132

46 in total

Review 1. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors: William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal: Antimicrob Agents Chemother Date: 2004-09 Impact factor: 5.191

Review 2. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors: M A Pfaller; D J Sheehan; J H Rex
Journal: Clin Microbiol Rev Date: 2004-04 Impact factor: 26.132

Review 3. Combination antifungal therapy.

Authors: Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

1. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.

2. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

3. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

4. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

5. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

6. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

7. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

8. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

9. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Review 10. Current and emerging azole antifungal agents.

Review 1. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Review 2. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Review 3. Combination antifungal therapy.

Review 4. Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Review 5. Aspergillus infections in transplant recipients.

6. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

7. Combination antifungal therapy for the treatment of invasive yeast and mold infections.

8. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.

9. In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp.

10. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.